Organicell Regenerative Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCEL research report →
About the company
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material.
- CEO
- Harry L. Leider FACPE,
- IPO
- 2016
- Employees
- 20
- HQ
- Miami, FL, US
Price Chart
- Market Cap
- $19.97M
- P/E
- -4.73
- P/S
- 2.86
- P/B
- 29.88
- EV/EBITDA
- 236.69
- Div Yield
- 0.00%
- Gross Margin
- 81.52%
- Op Margin
- -59.10%
- Net Margin
- -55.59%
- ROE
- 455.87%
- ROIC
- -511.01%
- Revenue
- $5.20M · 12.53%
- Net Income
- $-5,521,000 · -17.34%
- EPS
- $-0.86 · -16.22%
- Op Income
- $-5,386,000
- FCF YoY
- 48.90%
- 52W High
- $4.80
- 52W Low
- $0.90
- 50D MA
- $1.56
- 200D MA
- $2.21
- Beta
- 1.36
- Avg Volume
- 4.72K
Get TickerSpark's AI analysis on OCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 23 | Leider Harry L. | buy | 500,000 |
| Jun 28, 23 | Leider Harry L. | buy | 549,450 |
| Dec 19, 23 | Leider Harry L. | sell | 5,248 |
| Jul 7, 23 | Skycrest Holdings, LLC | buy | 320,710 |
| Jun 29, 23 | Skycrest Holdings, LLC | buy | 200,000 |
| Jun 28, 23 | Skycrest Holdings, LLC | buy | 400,000 |
| Jun 28, 23 | Leider Harry L. | buy | 549,450 |
| Jun 26, 23 | Skycrest Holdings, LLC | buy | 800,000 |
| Sep 6, 23 | Golub Howard Lawrence | other | 50,000,000 |
| Sep 6, 23 | Leider Harry L. | other | 57,000,000 |
Our OCEL coverage
Recent articles, reports, and earnings notes.
No research on OCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCEL report →Similar companies
Peers in the same neighborhood.